表紙
市場調査レポート

EpiCast Report:慢性リンパ性白血病の疫学的予測

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 301138
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
EpiCast Report:慢性リンパ性白血病の疫学的予測 EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023
出版日: 2014年05月01日 ページ情報: 英文 41 Pages
概要

慢性リンパ性白血病(CLL、慢性リンパ様白血病)とは、白血球(リンパ球)のがんの一種で、特定のリンパ球(B細胞)−−主に骨髄・血液内に集積し、感染症と闘う細胞です−−に悪影響を及ぼします。CLLは西欧諸国では一般的な白血病の形態で、年間平均発症率は人口10万人当たり5.0件(年齢問わず)となっています。基本的には高齢者が発症する疾患であり、40歳以下の患者の割合は10%以下となっています。世界の主要6ヶ国における発症件数は、2013年の37,795件から、2023年には45,683にまで増加する見通しで、その年平均成長率(CAGR)は2.09%と推計されています。また、治療済みの有病者数も、2013年の150,800人から、2023年には183,165にまで増加すると見られています(年平均成長率(CAGR)は2.15%)。

当レポートでは、世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における慢性リンパ性白血病(CLL)の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の発症・有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 近日刊行の関連調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 発症件数
    • 生存率:米国・欧州5ヶ国の場合
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:診断された発症件数
    • 予測の前提条件と手法:診断された有病者数(今後5年間分)
    • 予測の前提条件と手法:診断時のRai分類
  • 慢性リンパ性白血病(CLL)の疫学予測(今後11年間分)
    • 診断された発症件数
    • 診断された発症件数(年齢別)
    • 診断された発症件数(性別)
    • 診断された発症件数(年齢調整済み)
    • 診断された発症件数(診断時のRai分類別)
    • 診断された有病者数:今後5年間の予測
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER060

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 population in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.

GlobalData's epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by age- and sex-specific data for incidence and 1- to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages.

Scope

  • The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. GlobalData epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Survival from CLL - US and 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, Rai Stage at Diagnosis
  • 3.5. Epidemiological Forecast of CLL (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of CLL
    • 3.5.2. Age-Specific Diagnosed Incident Cases of CLL
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of CLL
    • 3.5.4. Age-Standardized Diagnosed Incidence of CLL
    • 3.5.5. Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis
    • 3.5.6. 5-Year Diagnosed Prevalent Cases of CLL
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: CLL Clinical Stages at Diagnosis
  • Table 2: Risk Factors and Comorbidities for CLL
  • Table 3: Trends in the Age-Adjusted Incidence of CLL in the US, All Ages, 2003-2010
  • Table 4: Trends in the Age-Adjusted Incidence of CLL(Cases per 100,000 Population) in France, All Ages, 1980-2012
  • Table 5: Trends in the 5-Year Relative Survival (%) of CLL in the US and 5EU, Both Sexes, 1993-2009
  • Table 6: Sources of Epidemiological Data Used for the Forecast for CLL Incident and Prevalent Cases, and the Rai Stage at Diagnosis
  • Table 7: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 8: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N (Row %), 2013
  • Table 9: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥40 Years, N (Row %), 2013
  • Table 10: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023

List of Figures

  • Figure 1: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥40 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Ages ≥40 Years, N, 2013
  • Figure 6: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
Back to Top